Humanized pertussis antibodies and uses thereof
US-9512204-B2 · Dec 6, 2016 · US
Humanized pertussis antibodies and uses thereof
US10035846B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10035846-B2 |
| Application number | US-201615356217-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 18, 2016 |
| Priority date | Mar 31, 2014 |
| Publication date | Jul 31, 2018 |
| Grant date | Jul 31, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to humanized antibodies which bind the pertussis toxin protein and their use as therapeutic agents. In particular, the present invention is directed to improved humanized 1B7 and 11E6 antibodies which bind the pertussis toxin protein.
First claim
Opening claim text (preview).
What is claimed is: 1. A humanized 11E6 antibody that binds a pertussis toxin protein, comprising an immunoglobulin heavy chain variable region and an immunoglobulin light chain variable region, wherein the immunoglobulin heavy chain variable region comprises an amino acid sequence selected from SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, or SEQ ID NO:18; and the immunoglobulin light chain variable region comprises an amino acid sequence selected from SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, or SEQ ID NO:24. 2. The humanized 11E6 antibody of claim 1 , wherein the immunoglobulin heavy chain variable region comprises the amino acid sequence of SEQ ID NO:18 and the immunoglobulin light chain variable region comprises the amino acid sequence of SEQ ID NO:23. 3. The humanized 11E6 antibody of claim 1 , wherein the antibody binds the pertussis toxin protein with a K D of 12 nM or lower. 4. A pharmaceutical composition comprising the humanized 11E6 antibody of claim 1 , and a pharmaceutically acceptable excipient.
Assignees
Inventors
Classifications
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
Antibacterial agents · CPC title
Antitussive agents · CPC title
- C07K16/1225Primary
from Bordetella (G) · CPC title
variable (Fv) region, i.e. VH and/or VL · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10035846B2 cover?
- The present invention relates to humanized antibodies which bind the pertussis toxin protein and their use as therapeutic agents. In particular, the present invention is directed to improved humanized 1B7 and 11E6 antibodies which bind the pertussis toxin protein.
- Who is the assignee on this patent?
- Univ Texas, Synthetic Biologics Inc
- What technology area does this patent fall under?
- Primary CPC classification C07K16/1225. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jul 31 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).